Benzinga
Published Mar 02, 2022 12:08
Updated Mar 02, 2022 12:40
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies.
Agios Pharmaceuticals, Inc.'s (NASDAQ: AGIO) Pyrukynd (mitapivat) was approved for the treatment of hemolytic anemia in people with pyruvate kinase deficiency. Hemolysis refers to the destruction of red blood cells.
Pyrukynd is a "new molecular entity," a term that refers to a drug containing an active moiety that hasn't been previously approved by the FDA. NME approval, therefore, is considered a measure of innovation in drug research.
Another NME that passed the FDA hurdle was Sanofi (PA:SASY)'s (NASDAQ: SNY) Enjaymo for the treatment of hemolysis in adults with cold agglutinin disease.
Reata Pharmaceuticals, Inc. (NASDAQ: RETA), as expected, received a complete response letter for its new drug application for bardoxolone methyl as a treatment option for Alport syndrome. An Adcom that met in early December voted against recommending approval of the drug.
PDUFA dates are key "binary or make-or-break catalysts" for biopharma companies. These are dates by which the drug regulator is required to announce its verdict on regulatory applications filed with it, following either a standard review period or priority review.
Here are the key PDUFA dates scheduled for February.
Click here to access Benzinga's FDA Calendar
Bristol-Myers Squibb Seeks Nod For Skin Cancer Combo Therapy
The FDA accepted the company's regulatory application for priority review in September 2021.
Marinus Positive On Seizure Drug Approval
The FDA accepted for priority review the company's NDA, seeking approval for ganaxolone as a treatment option for seizures associated with CDKL5 deficiency disorder, in September. This is a rare genetic epilepsy.
Marinus management is confident of approval coming through and is expecting no REMS or black box warning on the label, SVB Leerink analyst Marc Goodman said in a mid-February note. The company is looking ahead to a launch timeline of July following the 90-day Drug Enforcement Administration scheduling process.
The company recently announced a delay in the readout from the Phase 3 study of intravenous ganaxolone in refractory status epilepticus, citing omicron impact and an interruption of clinical supply material associated with the drug.
Will Zogenix Gain Label Expansion For Seizure Drug?
Zogenix has recently announced an agreement to be acquired by Belgian biopharma UCB.
TG Therapeutics Could See A Pushback In Blood Cancer Combo Therapy Review
TG Therapeutics' application seeks approval for ublituximab, an antibody treatment, along with Ukoniq for VLL and SLL. It was accepted for review in May 2021. The company said in November the FDA has notified it regarding a proposed meeting of the Oncologic Drugs Advisory Committee in connection with its review. With still no word on a confirmed date for the Adcom meeting, a decision by the stipulated date is unlikely.
Related Link: Moderna (NASDAQ:MRNA) Rallies After Q4 Earnings: What 2 Analysts Have To Say About COVID-19 Stock
Bristol-Myers Squibb Awaits Third Nod For Reblozyl
Can Merck Snag Another Approval For Keytruda?
Lipocine Aims To Convert Tlando Tentative Approval To Full Approval
Lipocine has an exclusive licensing agreement with Antares for marketing Tlando in the U.S.
Akebia Hopes For Positive Tidings On Anemia Drug
Adcom Calendar FDA's Peripheral and Central Nervous System Drugs Advisory Committee is scheduled to meet on March 30 to discuss Amylyx Pharmaceuticals, Inc.'s (NASDAQ: AMLX) NDA for sodium phenylbutyrate/taurursodiol powder for oral suspension, for the treatment of amyotrophic lateral sclerosis.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read at Benzinga
Read the original article on Benzinga
Written By: Benzinga
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.